Henry Schein (NASDAQ:HSIC) Stock Rating Lowered by Wall Street Zen

Henry Schein (NASDAQ:HSIC) was downgraded by Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research report issued to clients and investors on Saturday.

HSIC has been the topic of a number of other research reports. Mizuho boosted their price objective on Henry Schein from $81.00 to $88.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 25th. UBS Group increased their target price on Henry Schein from $79.00 to $87.00 and gave the company a “neutral” rating in a research report on Wednesday, February 25th. Barclays started coverage on Henry Schein in a research note on Monday, December 8th. They set an “overweight” rating and a $86.00 price target on the stock. Wells Fargo & Company upped their price objective on Henry Schein from $76.00 to $87.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 25th. Finally, Barrington Research set a $97.00 price objective on shares of Henry Schein and gave the company an “outperform” rating in a report on Wednesday, February 25th. Six equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $85.58.

Henry Schein Price Performance

Shares of NASDAQ:HSIC opened at $75.57 on Friday. The company has a market cap of $8.67 billion, a price-to-earnings ratio of 23.11, a PEG ratio of 2.24 and a beta of 0.87. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.38 and a quick ratio of 0.76. The firm has a 50 day simple moving average of $78.21 and a 200 day simple moving average of $72.89. Henry Schein has a one year low of $60.56 and a one year high of $89.29.

Henry Schein (NASDAQ:HSIC) last issued its earnings results on Tuesday, February 24th. The company reported $1.34 earnings per share for the quarter, beating analysts’ consensus estimates of $1.30 by $0.04. The firm had revenue of $3.44 billion for the quarter, compared to analyst estimates of $3.34 billion. Henry Schein had a net margin of 3.02% and a return on equity of 15.16%. The company’s quarterly revenue was up 7.7% on a year-over-year basis. During the same quarter last year, the business posted $1.19 earnings per share. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. Research analysts predict that Henry Schein will post 4.74 earnings per share for the current fiscal year.

Insider Transactions at Henry Schein

In related news, CEO Stanley M. Bergman sold 43,812 shares of the stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $81.31, for a total value of $3,562,353.72. Following the transaction, the chief executive officer directly owned 383,803 shares in the company, valued at $31,207,021.93. This trade represents a 10.25% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Kurt P. Kuehn sold 2,844 shares of Henry Schein stock in a transaction on Tuesday, March 10th. The shares were sold at an average price of $78.96, for a total transaction of $224,562.24. Following the completion of the sale, the director directly owned 15,420 shares of the company’s stock, valued at approximately $1,217,563.20. The trade was a 15.57% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 104,556 shares of company stock valued at $8,476,351 in the last 90 days. 1.14% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Henry Schein

Several hedge funds and other institutional investors have recently made changes to their positions in HSIC. Westwood Holdings Group Inc. purchased a new stake in shares of Henry Schein in the second quarter worth approximately $20,631,000. AlphaQuest LLC boosted its position in shares of Henry Schein by 91.8% during the third quarter. AlphaQuest LLC now owns 20,861 shares of the company’s stock valued at $1,385,000 after buying an additional 9,987 shares during the last quarter. Berger Financial Group Inc bought a new stake in Henry Schein during the third quarter worth $2,981,000. Marshall Wace LLP grew its holdings in Henry Schein by 230.7% during the second quarter. Marshall Wace LLP now owns 310,166 shares of the company’s stock worth $22,658,000 after buying an additional 216,389 shares in the last quarter. Finally, SVB Wealth LLC purchased a new stake in Henry Schein in the 2nd quarter valued at $1,415,000. 96.62% of the stock is owned by institutional investors.

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.